

Product Name: PD 173074 Revision Date: 01/10/2021

# **Product Data Sheet**

3

PE

# PD 173074

Cat. No.:	A8253
CAS No.:	219580-11-7
Formula:	C28H41N7O3
M.Wt:	523.67
Synonyms:	PD 173074,PD-173074
Target:	Tyrosine Kinase
Pathway:	FGFR
Storage:	Store at 4°C
	210

## Solvent & Solubility

	≥26.18 mg/mL in DN	$\geq$ 26.18 mg/mL in DMSO; insoluble in H2O; $\geq$ 108.4 mg/mL in EtOH with ultrasonic			
Prepar In Vitro Stock S	Preparing	Mass Solvent Concentration	1mg	5mg	10mg
	Slock Solutions	1 mM	1.9096 mL	9.5480 mL	19.0960 mL
	810	5 mM	0.3819 mL	1.9096 mL	3.8192 mL
	PERMIT	10 mM	0.1910 mL	0.9548 mL	1.9096 mL

Please refer to the solubility information to select the appropriate solvent.

## **Biological Activity**

Shortsummary FGFR inhibitor

IC<sub>50</sub> & Target

In Vitro

~25 nM (FGFR1), 100-200 nM (VEGFR2)

Cell Viability Assay	and the second se
Cell Line:	NIH 3T3 cells
Preparation method:	The solubility of this compound in DMSO is >10 mM. General tips for obtaining
	shake it in the ultrasonic bath for a while. Stock solution can be stored below
	-20 °C for several months.
Reacting conditions:	0 ~ 1000 nM; 5 mins
	1 www.apexbt.com

	Applications:	PD 173074 dose-dependently inhibited autophosphorylation of FGFR1, with an			
		IC50 value in the range of 1 ~ 5 nM. In addition, PD 173074 inhibited			
		autophosphorylation of VEGFR2 with an IC50 value of 100 ~ 200 nM.			
	Animal experiment	Animal experiment			
In Vivo	Animal models:	Swiss Webster mice with induced corneal angiogenesis			
	Dosage form:	1 or 2 mg/kg/day; i.p.			
	Applications:	At the dose of 1 or 2 mg/kg, PD 173074 significantly inhibited angiogenesis			
	Contraction of the second	induced by either FGF or VEGF in a dose-dependent manner. Besides, it			
	es alles	showed no apparent toxicity.			
	Other notes:	Please test the solubility of all compounds indoor, and the actual solubility may			
		slightly differ with the theoretical value. This is caused by an experimenta			
		system error and it is normal.			

### **Product Citations**



See more customer validations on www.apexbt.com.

### References

[1]. Mohammadi M, Froum S, Hamby JM, Schroeder MC, Panek RL, Lu GH, Eliseenkova AV, Green D, Schlessinger J, Hubbard SR. Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain. EMBO J. 1998 Oct 15;17(20):5896-904.

#### Caution

#### FOR RESEARCH PURPOSES ONLY.

#### NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

Specific storage and handling information for each product is indicated on the product datasheet. Most APExBIO products are stable under the recommended conditions. Products are sometimes shipped at a temperature that differs from the recommended storage temperature. Shortterm storage of many products are stable in the short-term at temperatures that differ from that required for long-term storage. We ensure that the product is shipped under conditions that will maintain the quality of the reagents. Upon receipt of the product, follow the storage recommendations on the product data sheet.



### **APExBIO Technology**

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054. Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com















